Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

NCT00687219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic
Liver Cirrhosis

Interventions

BIOLOGICAL: Peginterferon alfa-2b
DRUG: Ribavirin

Sponsor

Merck Sharp & Dohme LLC